论文部分内容阅读
中国关键性Ⅲ期临床研究达到主要终点——作为一线治疗显著延长中国RAS野生型转移性结直肠癌(mCRC)患者的无进展生存期默克将与相关机构合作,努力尽早将爱必妥作为一线治疗服务于中国患者这是默克的肿瘤治疗战略在成长型市场的主要里程碑式研究结果2016年4月2 5日——全球领先的科技公司默克在德国达姆施塔特宣布,中国TAILOR关键性
Key Chinese Phase III Clinical Studies Achieve Primary Endpoint - Progression-Free Survival as a First-Line Treatment for Patients with Chinese RAS Wild-type Metastatic Colorectal Cancer (mCRC) Merck, in collaboration with the agency concerned, will strive to incorporate Erbitux as an early First-line treatment to serve Chinese patients This is a key milestone for Merck’s cancer treatment strategy in growth markets April 25, 2016 - Merck, the world’s leading technology company, announced in Darmstadt, Germany, that China TAILOR key